Interpret of international Delphi consensus on the management of aquaporin-4 immunoglobulin G seropositive neuromyelitis optica spectrum disorder
10.3760/cma.j.cn511434-20230621-00281
- VernacularTitle:水通道蛋白4抗体阳性视神经脊髓炎谱系疾病治疗国际共识解读
- Author:
Yuyu LI
1
;
Shihui WEI
;
Huanfen ZHOU
Author Information
1. 解放军总医院第三医学中心眼科医学部, 北京 100853
- Keywords:
Neuromyelitis optica spectrum disorder;
Eculizumab;
Inebilizumab;
Satralizumab;
Consensus interpretation
- From:
Chinese Journal of Ocular Fundus Diseases
2023;39(7):525-529
- CountryChina
- Language:Chinese
-
Abstract:
Neuromyelitis optica spectrum disorder (NMOSD) is a rare debilitating autoimmune disease of the central nervous system. Three monoclonal antibodies were recently approved as maintenance therapies for aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive NMOSD (eculizumab, inebilizumab, and satralizumab). Neurol Neuroimmunol Neuroinflamm published international Delphi consensus on the management of AQP4-IgG+ NMOSD in May 31, 2023. Twenty-five statements reached consensus after two voting rounds by 24 Delphi panel experts. Inebilizumab and satralizumab have been listed in China, and off-label immunosuppressants and biologics are also used in clinical practice. However, there are no standard treatment recommendations in use of these biologics and maintenance therapy of NMOSD. Therefore, the interpretation of this consensus, focusing on the initial use of monoclonal drugs, the conversion between monoclonal drugs and immunosuppressants, as well as the application and safety of special populations, is conducive to improving the normative and effective use of of monoclonal drugs in NMOSD y ophthalmologists and neurologists
